These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 38396367)

  • 81. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Downregulation of PD-L1 and HLA-I in non-small cell lung cancer with ALK fusion.
    Mu D; Guo J; Yu W; Zhang J; Ren X; Han Y
    Thorac Cancer; 2022 Apr; 13(8):1153-1163. PubMed ID: 35253386
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients 
with Advanced EGFR Positive NSCLC and Its Relationship with the 
Therapeutic Efficacy of EGFR-TKIs].
    Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib.
    Zhou Y; Song L; Xu Q; Zeng L; Jiang W; Yang N; Zhang Y
    Lung Cancer; 2022 May; 167():58-64. PubMed ID: 35405360
    [TBL] [Abstract][Full Text] [Related]  

  • 85. PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation.
    Ma L; Lv J; Dong Y; Zhang X; Li X; Zhang H; Nong J; Zhang Q; Qin N; Yang X; Wang J; Zhang S
    Interdiscip Sci; 2019 Jun; 11(2):266-272. PubMed ID: 31098955
    [TBL] [Abstract][Full Text] [Related]  

  • 86. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
    Takada K; Toyokawa G; Tagawa T; Kohashi K; Shimokawa M; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
    Lung Cancer; 2018 Feb; 116():1-6. PubMed ID: 29413045
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8
    Li Y; Shi X; Mao B; Wang L; Wu L; Li J; Jiao S
    Lung Cancer; 2022 Apr; 166():161-169. PubMed ID: 35287068
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.
    Bylicki O; Paleiron N; Margery J; Guisier F; Vergnenegre A; Robinet G; Auliac JB; Gervais R; Chouaid C
    Target Oncol; 2017 Oct; 12(5):563-569. PubMed ID: 28624922
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.
    Watanabe H; Ohashi K; Nishii K; Seike K; Makimoto G; Hotta K; Maeda Y; Kiura K
    Intern Med; 2019 Oct; 58(20):3033-3037. PubMed ID: 31292383
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
    Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
    Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
    Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
    Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
    [TBL] [Abstract][Full Text] [Related]  

  • 92. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
    Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
    Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion.
    Pan Y; Liu X; Zhang W; Wang W; Wang H; Luo L; Jia K; Shao C; Mao S; Qiu T; Ni J; Yu J; Wang L; Chen B; Xiong A; Gao G; Chen X; Wu F; Zhou C; Wu C; Ren S
    Lung Cancer; 2023 Jul; 181():107233. PubMed ID: 37201296
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
    Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
    Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
    Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
    [TBL] [Abstract][Full Text] [Related]  

  • 98. PD-L1 (22C3) Expression Correlates with Clinical and Molecular Features of Lung Adenocarcinomas in Cytological Samples.
    Anderson SA; Harbi D; Oramas Mogrovejo D; Floyd AD; Eltoum IE; Fatima H; Rosenblum F; Lora Gonzalez M; Lin D; Mackinnon AC; Siegal GP; Winokur T; Yalniz C; Huo L; Harada S; Huang X
    Acta Cytol; 2023; 67(5):507-518. PubMed ID: 37494911
    [TBL] [Abstract][Full Text] [Related]  

  • 99. EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.
    Alves Pinto I; de Oliveira Cavagna R; Virginio da Silva AL; Dias JM; Santana IV; Souza LC; Ferreira da Silva FA; Biazotto Fernandes MF; Junqueira Pinto GD; Negreiros IS; Santiago Gonçalves MF; de Paula FE; Berardinelli GN; Casagrande GMS; Oliveira da Silva M; Albino da Silva EC; de Oliveira MA; Jacinto AA; Duval da Silva V; Reis RM; De Marchi P; Leal LF
    Oncologist; 2022 Nov; 27(11):e899-e907. PubMed ID: 36099421
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.
    Roussel H; De Guillebon E; Biard L; Mandavit M; Gibault L; Fabre E; Antoine M; Hofman P; Beau-Faller M; Blons H; Danel C; Barthes FLP; Gey A; Granier C; Wislez M; Laurent-Puig P; Oudard S; Bruneval P; Badoual C; Cadranel J; Tartour E
    Oncoimmunology; 2017; 6(4):e1286437. PubMed ID: 28507793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.